As much as antithrombotic therapies have done to save lives and address thrombosis associated with problems ranging from ischemic stroke to acute myocardial infarction, Vascular Therapeutics Inc. believes there are improvements to be made.

The company is tackling the limitations associated with available antithrombotics - thrombolytics, anti-platelet compounds and direct thrombin inhibitors - through a greater understanding of the molecular mechanisms responsible for the excessive blood clotting associated with acute cardiovascular diseases.